Last week, Aimed Alliance Executive Director, Stacey L. Worthy, was quoted in an article in Modern Medicine Network, entitled Supreme Court Ruling Raises Biosimilars’ Access. The article notes that a recent Supreme Court decision allows biosimilar manufacturers to start advertising their drugs before they know the indications for which the U.S. Food and Drug Administration (FDA) will approve the drug. Aimed Alliance supports the development of biosimilars in efforts to provide patients with additional treatment options and to increase drug competition, ultimately leading to lower drug prices. However, Ms. Worthy notes that “while the ruling allows biosimilars to be marketed sooner, it could lead to confusion and improper prescribing if the FDA approves the drug for different indications than what the manufacturer had been advertising the drug for.” The full article is available here.
Last Updated on May 13, 2020 by Aimed Alliance
